Novartis acquires developers of Lu-177 PSMA-617 and Ac-225 PSMA-617

The major, Switzerland-based, global pharmaceutical company Novartis has just agreed to acquire Endocyte — the developer of both Lu-177- PSMA-617 and Ac-225-PSMA-617, which are in clinical trials for the treatment of advanced forms of prostate cancer. The fact that Novartis was willing to pay something like US$2.1 billion to acquire Endocyte probably tells us something about their confidence that one or both of these products will be coming to market in the next few years!

This is especially true when one realizes that, not so long ago, Novartis also paid US$3.9 billion to acquire a different company (Advanced Accelerator Applications) through which the Swiss drugmaker gained Lutathera (lutetium Lu-177 dotatate), which is already approved in both the US and Europe for the treatment of  a relative rare group of cancers known as somatostatin-receptor positive gastroenteropancreatic neuroendocrine tumors.

For additional information about this acquisition, see here, or see the Novartis media release.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: